Effects of rosiglitazone on intramyocellular lipid accumulation in Psammomys obesus

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1802, Issue 2, 2010, Pages 235-239

  Molero, Juan Carlos ^a   Lee, Scott ^a   Leizerman, Ilit ^b   Chajut, Ayelet ^b   Cooper, Adrian ^a   Walder, Ken ^a  

^a DEAKIN UNIVERSITY   (Australia)

^b QuantomiX Ltd   (Israel)

Author keywords

Intramyocellular lipid; Psammomys obesus; Rosiglitazone; Thiazolidinedione

Indexed keywords

FAT DROPLET; GLUCOSE; INSULIN; LIPID; ROSIGLITAZONE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY COMPOSITION; BODY FAT; CALORIMETRY; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; ELECTRON MICROSCOPY; GASTROCNEMIUS MUSCLE; GLUCOSE TOLERANCE; HEART WEIGHT; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID COMPOSITION; LIVER WEIGHT; MALE; MUSCLE CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; ORGAN WEIGHT; PRIORITY JOURNAL; PSAMMOMYS OBESUS; SCANNING ELECTRON MICROSCOPY; SKELETAL MUSCLE; SPLEEN WEIGHT; TESTIS WEIGHT; TREATMENT DURATION; TREATMENT OUTCOME;

ADIPOSE TISSUE; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; DIETARY CARBOHYDRATES; GERBILLINAE; GLUCOSE TOLERANCE TEST; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INTRACELLULAR SPACE; LIPIDS; MALE; THIAZOLIDINEDIONES;

ANIMALIA; PSAMMOMYS OBESUS;

EID: 74149090815     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2009.10.002     Document Type: Article

References (43)

1. Oakes N.D., Kennedy C.J., Jenkins A.B., Laybutt D.R., Chisholm D.J., and Kraegen E.W. A new antidiabetic agent BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes 43 (1994) 1203-1210
2. Young P.W., Cawthorne M.A., Coyle P.J., Holder J.C., Holman G.D., Kozka I.J., Kirkham D.M., Lister C.A., and Smith S.A. Repeat treatment of obese mice with BRL 49653, a new potent insulin sensitizer, enhances insulin action in white adipocytes. Association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labeling. Diabetes 44 (1995) 1087-1092
3. Nolan J.J., Jones N.P., Patwardhan R., and Deacon L.F. Rosiglitazone taken once daily provides effective glycaemic control in patients with Type 2 diabetes mellitus. Diabet. Med. 17 (2000) 287-294
4. Phillips L.S., Grunberger G., Miller E., Patwardhan R., Rappaport E.B., and Salzman A. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 24 (2001) 308-315
5. Ibrahimi A., Teboul L., Gaillard D., Amri E.Z., Ailhaud G., Young P., Cawthorne M.A., and Grimaldi P.A. Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells. Mol. Pharmacol. 46 (1994) 1070-1076
6. Oakes N.D., Camilleri S., Furler S.M., Chisholm D.J., and Kraegen E.W. The insulin sensitizer BRL 49653, reduces systemic fatty acid supply and utilization and tissue lipid availability in the rat. Metabolism 46 (1997) 935-942
7. Hevener A.L., He W., Barak Y., Le J., Bandyopadhyay G., Olson P., Wilkes J., Evans R.M., and Olefsky J. Muscle-specific Pparg deletion causes insulin resistance. Nat. Med. 9 (2003) 1491-1497
8. Hevener A.L., Olefsky J.M., Reichart D., Nguyen M.T., Bandyopadyhay G., Leung H.Y., Watt M.J., Benner C., Febbraio M.A., Nguyen A.K., Folian B., Subramaniam S., Gonzalez F.J., Glass C.K., and Ricote M. Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J. Clin. Invest. 117 (2007) 1658-1669
9. Sanchez J.C., Converset V., Nolan A., Schmid G., Wang S., Heller M., Sennitt M.V., Hochstrasser D.F., and Cawthorne M.A. Effect of rosiglitazone on the differential expression of diabetes-associated proteins in pancreatic islets of C57Bl/6 lep/lep mice. Mol. Cell. Proteomics 1 (2002) 509-516
10. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., and Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 270 (1995) 12953-12956
11. Shulman G.I. Cellular mechanisms of insulin resistance. J. Clin. Invest. 106 (2000) 171-176
12. Yuan M., Konstantopoulos N., Lee J., Hansen L., Li Z.W., Karin M., and Shoelson S.E. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 293 (2001) 1673-1677
13. Hundal R.S., Petersen K.F., Mayerson A.B., Randhawa P.S., Inzucchi S., Shoelson S.E., and Shulman G.I. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J. Clin. Invest. 109 (2002) 1321-1326
14. Arkan M.C., Hevener A.L., Greten F.R., Maeda S., Li Z.W., Long J.M., Wynshaw-Boris A., Poli G., Olefsky J., and Karin M. IKK-beta links inflammation to obesity-induced insulin resistance. Nat. Med. 11 (2005) 191-198
15. Ricote M., Li A.C., Willson T.M., Kelly C.J., and Glass C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391 (1998) 79-82
16. Jiang C., Ting A.T., and Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391 (1998) 82-86
17. Mohanty P., Aljada A., Ghanim H., Hofmeyer D., Tripathy D., Syed T., Al-Haddad W., Dhindsa S., and Dandona P. Evidence for a potent antiinflammatory effect of rosiglitazone. J. Clin. Endocrinol. Metab. 89 (2004) 2728-2735
18. van Doorn M., Kemme M., Ouwens M., van Hoogdalem E.J., Jones R., Romijn H., de Kam M., Schoemaker R., Burggraaf K., and Cohen A. Evaluation of proinflammatory cytokines and inflammation markers as biomarkers for the action of thiazolidinediones in Type 2 diabetes mellitus patients and healthy volunteers. Br. J. Clin. Pharmacol. 62 (2006) 391-402
19. Storlien L.H., Jenkins A.B., Chisholm D.J., Pascoe W.S., Khouri S., and Kraegen E.W. Influence of dietary fat composition on development of insulin resistance in rats. Relationship to muscle triglyceride and omega-3 fatty acids in muscle phospholipid. Diabetes 40 (1991) 280-289
20. Kraegen E.W., Clark P.W., Jenkins A.B., Daley E.A., Chisholm D.J., and Storlien L.H. Development of muscle insulin resistance after liver insulin resistance in high-fat-fed rats. Diabetes 40 (1991) 1397-1403
21. Krssak M., Falk Petersen K., Dresner A., DiPietro L., Vogel S.M., Rothman D.L., Roden M., and Shulman G.I. Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study. Diabetologia 42 (1999) 113-116
22. Pan D.A., Lillioja S., Kriketos A.D., Milner M.R., Baur L.A., Bogardus C., Jenkins A.B., and Storlien L.H. Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes 46 (1997) 983-988
23. Kelley D.E., Goodpaster B., Wing R.R., and Simoneau J.A. Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss. Am. J. Physiol. 277 (1999) E1130-E1141
24. Russell A.P., Gastaldi G., Bobbioni-Harsch E., Arboit P., Gobelet C., Deriaz O., Golay A., Witztum J.L., and Giacobino J.P. Lipid peroxidation in skeletal muscle of obese as compared to endurance-trained humans: a case of good vs. bad lipids. FEBS Lett. 551 (2003) 104-106
25. Goodpaster B.H., He J., Watkins S., and Kelley D.E. Skeletal muscle lipid content and insulin resistance: evidence for a paradox in endurance-trained athletes. J. Clin. Endocrinol. Metab. 86 (2001) 5755-5761
26. Bruce C.R., Kriketos A.D., Cooney G.J., and Hawley J.A. Disassociation of muscle triglyceride content and insulin sensitivity after exercise training in patients with Type 2 diabetes. Diabetologia 47 (2004) 23-30
27. Kim J.K., Fillmore J.J., Gavrilova O., Chao L., Higashimori T., Choi H., Kim H.J., Yu C., Chen Y., Qu X., Haluzik M., Reitman M.L., and Shulman G.I. Differential effects of rosiglitazone on skeletal muscle and liver insulin resistance in A-ZIP/F-1 fatless mice. Diabetes 52 (2003) 1311-1318
28. Jucker B.M., Schaeffer T.R., Haimbach R.E., Mayer M.E., Ohlstein D.H., Smith S.A., Cobitz A.R., and Sarkar S.K. Reduction of intramyocellular lipid following short-term rosiglitazone treatment in Zucker fatty rats: an in vivo nuclear magnetic resonance study. Metabolism 52 (2003) 218-225
29. Koh E.H., Kim M.S., Park J.Y., Kim H.S., Youn J.Y., Park H.S., Youn J.H., and Lee K.U. Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation. Diabetes 52 (2003) 2331-2337
30. Hockings P.D., Changani K.K., Saeed N., Reid D.G., Birmingham J., O'Brien P., Osborne J., Toseland C.N., and Buckingham R.E. Rapid reversal of hepatic steatosis, and reduction of muscle triglyceride, by rosiglitazone: MRI/S studies in Zucker fatty rats. Diabetes Obes. Metab. 5 (2003) 234-243
31. Kuhlmann J., Neumann-Haefelin C., Belz U., Kalisch J., Juretschke H.P., Stein M., Kleinschmidt E., Kramer W., and Herling A.W. Intramyocellular lipid and insulin resistance: a longitudinal in vivo 1H-spectroscopic study in Zucker diabetic fatty rats. Diabetes 52 (2003) 138-144
32. Mayerson A.B., Hundal R.S., Dufour S., Lebon V., Befroy D., Cline G.W., Enocksson S., Inzucchi S.E., Shulman G.I., and Petersen K.F. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 51 (2002) 797-802
33. Lessard S.J., Lo Giudice S.L., Lau W., Reid J.J., Turner N., Febbraio M.A., Hawley J.A., and Watt M.J. Rosiglitazone enhances glucose tolerance by mechanisms other than reduction of fatty acid accumulation within skeletal muscle. Endocrinology 145 (2004) 5665-5670
34. Muurling M., Mensink R.P., Pijl H., Romijn J.A., Havekes L.M., and Voshol P.J. Rosiglitazone improves muscle insulin sensitivity, irrespective of increased triglyceride content, in ob/ob mice. Metabolism 52 (2003) 1078-1083
35. Barnett M., Collier G.R., Collier F.M., Zimmet P., and O'Dea K. A cross-sectional and short-term longitudinal characterisation of NIDDM in Psammomys obesus. Diabetologia 37 (1994) 671-676
36. Walder K.R., Fahey R.P., Morton G.J., Zimmet P.Z., and Collier G.R. Characterization of obesity phenotypes in Psammomys obesus (Israeli sand rats). Int. J. Exp. Diabetes Res. 1 (2000) 177-184
37. Thiberge S., Nechushtan A., Sprinzak D., Gileadi O., Behar V., Zik O., Chowers Y., Michaeli S., Schlessinger J., and Moses E. Scanning electron microscopy of cells and tissues under fully hydrated conditions. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 3346-3351
38. Nyska A., Cummings C.A., Vainshtein A., Nadler J., Ezov N., Grunfeld Y., Gileadi O., and Behar V. Electron microscopy of wet tissues: a case study in renal pathology. Toxicol. Pathol. 32 (2004) 357-363
39. Nyska A., Horowitz M., Anaby D., Sabban A., Leizerman I., Blaugrund E., Mayk A., and Behar V. A new method of wet scanning electron microscopy for the analysis of myelination in EAE mouse model of multiple sclerosis. Exp. Toxicol. Pathol. 57 (2006) 291-297
40. Hefetz S., Ziv E., Jorns A., Lenzen S., and Shafrir E. Prevention of nutritionally induced diabetes by rosiglitazone in the gerbil Psammomys obesus. Diabetes. Metab. Res. Rev. 22 (2006) 139-145
41. Fraenkel M., Weiss R., Leizerman I., Anaby D., Golomb E., Leibowitz G., and Kaiser N. Scanning electron microscopic analysis of intramyocellular lipid droplets in an animal model of type 2 diabetes. Obesity (Silver Spring) 16 (2008) 695-699
42. He J., Goodpaster B.H., and Kelley D.E. Effects of weight loss and physical activity on muscle lipid content and droplet size. Obes. Res. 12 (2004) 761-769
43. Hesselink M.K., Mensink M., and Schrauwen P. Intramyocellular lipids and insulin sensitivity: does size really matter?. Obes. Res. 12 (2004) 741-742